Details for Patent: 8,480,631
✉ Email this page to a colleague
Which drugs does patent 8,480,631 protect, and when does it expire?
Patent 8,480,631 protects OTREXUP and is included in one NDA.
This patent has twelve patent family members in seven countries.
Summary for Patent: 8,480,631
| Title: | Hazardous agent injection system |
| Abstract: | A hazardous agent injection system including from about 0.02 ml to about 4.0 ml of methotrexate at a concentration of from about 7.5 mg/ml to about 150 mg/ml; a needle-assisted jet injector including a container configured to contain the methotrexate; a injection outlet member associated with the container; an injection-assisting needle coupled to the injection outlet member; a firing mechanism associated with the container; an energy source associated with the firing mechanism; and a trigger mechanism associated with the firing mechanism, wherein the needle-assisted jet injector is configured to eject the methotrexate from the injection outlet member such that the C.sub.max, T.sub.max and bioavailability of the needle-assisted jet injected methotrexate falls between about 80% and about 125% of the C.sub.max, T.sub.max and bioavailability of methotrexate delivered by a hand-powered syringe. |
| Inventor(s): | Wotton; Paul (Stamford, CT), Sadowsky; Peter L. (Woodbury, MN), Hayes; John William (Chaska, MN) |
| Assignee: | Antares Pharma, Inc. (Ewing, NJ) |
| Application Number: | 13/607,659 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,480,631 |
|
Patent Claim Types: see list of patent claims | Dosage form; Use; |
Drugs Protected by US Patent 8,480,631
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | ⤷ Sign Up | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-001 | Oct 11, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | ⤷ Sign Up | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-006 | Mar 24, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | ⤷ Sign Up | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | ⤷ Sign Up | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-007 | Mar 24, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | ⤷ Sign Up | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | ⤷ Sign Up | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-008 | Mar 24, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,480,631
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010226442 | ⤷ Sign Up | |||
| Canada | 2755779 | ⤷ Sign Up | |||
| China | 102612381 | ⤷ Sign Up | |||
| European Patent Office | 2408493 | ⤷ Sign Up | |||
| Japan | 2012521224 | ⤷ Sign Up | |||
| Japan | 2015042270 | ⤷ Sign Up | |||
| Japan | 2016104214 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
